CMS-0062: Why Drug Prior Authorization Is Only Part of the Story
If you’ve only skimmed the trade-press coverage of CMS-0062, you’d think the rule is about one thing: extending CMS-0057’s prior authorization framework to drugs covered under the medical benefit. That extension is real and it matters. It isn’t the story. The story is what CMS is doing around it. Assuming of course, that the rule is finalized in broad alignment with the proposed rule. CMS-0062 reaches deeper into payer […]